Is TLPH or ZNTL more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Zentalis Pharmaceuticals N/A -70.18% -51.46%

Do analysts rate ACB or TLPH?

Talphera has a consensus target price of $3.00, indicating a potential upside of 158.62%. Given Talphera's higher probable upside, analysts plainly believe Talphera is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is ACB or TLPH more profitable?

Talphera has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Aurora Cannabis -32.26% 4.37% 3.45% Talphera N/A -87.28% -51.36%

Is CRDL or TLPH more profitable?

Talphera's return on equity of -87.28% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -180.44% -140.28% Talphera N/A -87.28% -51.36%

Do analysts rate SIGA or TLPH?

Talphera has a consensus price target of $3.00, suggesting a potential upside of 158.62%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer TLPH or SBTX?

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 158.62%. Given Talphera's stronger consensus rating and higher probable upside, analysts clearly believe Talphera is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is TLPH or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Talphera's return on equity. Company Net Margins Return on Equity Return on Assets Talphera N/A -87.28% -51.36% Silverback Therapeutics N/A -29.62% -28.20%

Talphera (TLPH) Competitors

$1.16 -0.01 (-0.85%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.16 0.00 (0.00%)

As of 09/18/2026 04:15 PM Eastern

Compare

TLPH vs. ZNTL, ACB, CRDL, SIGA, and SBTX

Should you buy Talphera stock or one of its competitors? Talphera's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL), Siga Technologies (SIGA), and Silverback Therapeutics (SBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Talphera compare to Zentalis Pharmaceuticals?

Talphera (NASDAQ:TLPH) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 158.62%. Zentalis Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 117.04%. Given Talphera's higher probable upside, equities analysts clearly believe Talphera is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Talphera has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$1K	60,210.96	-$14.29M	-$0.27	N/A
Zentalis Pharmaceuticals	$67.43M	3.31	-$137.06M	-$1.95	N/A

Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, indicating that its share price is 85% more volatile than the broader market.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

37.7% of Talphera shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Talphera. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for Talphera. Zentalis Pharmaceuticals' average media sentiment score of 0.17 beat Talphera's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Talphera	Neutral
Zentalis Pharmaceuticals	Neutral

Summary

Zentalis Pharmaceuticals beats Talphera on 9 of the 15 factors compared between the two stocks.

How does Talphera compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Talphera has lower revenue, but higher earnings than Aurora Cannabis. Talphera is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.01	-$88.13M	-$1.41	N/A
Talphera	$1K	60,210.96	-$14.29M	-$0.27	N/A

Talphera has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Talphera	N/A	-87.28%	-51.36%

Talphera has a consensus target price of $3.00, indicating a potential upside of 158.62%. Given Talphera's higher probable upside, analysts plainly believe Talphera is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 3.5% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Aurora Cannabis had 9 more articles in the media than Talphera. MarketBeat recorded 9 mentions for Aurora Cannabis and 0 mentions for Talphera. Aurora Cannabis' average media sentiment score of 0.15 beat Talphera's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Talphera	Neutral

Aurora Cannabis has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market.

Summary

Aurora Cannabis beats Talphera on 9 of the 17 factors compared between the two stocks.

How does Talphera compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Talphera. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 0 mentions for Talphera. Cardiol Therapeutics' average media sentiment score of 0.47 beat Talphera's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Talphera	Neutral

Talphera has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Talphera	$1K	60,210.96	-$14.29M	-$0.27	N/A

Cardiol Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 433.33%. Talphera has a consensus target price of $3.00, indicating a potential upside of 158.62%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cardiol Therapeutics has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Talphera's return on equity of -87.28% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Talphera	N/A	-87.28%	-51.36%

Summary

Cardiol Therapeutics beats Talphera on 8 of the 14 factors compared between the two stocks.

How does Talphera compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Talphera (NASDAQ:TLPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Siga Technologies has higher revenue and earnings than Talphera. Siga Technologies is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.39	$23.28M	-$0.05	N/A
Talphera	$1K	60,210.96	-$14.29M	-$0.27	N/A

Talphera has a consensus price target of $3.00, suggesting a potential upside of 158.62%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 37.7% of Talphera shares are held by institutional investors. 2.7% of Siga Technologies shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Talphera has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Siga Technologies' return on equity of -1.55% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Talphera	N/A	-87.28%	-51.36%

Siga Technologies has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Talphera has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

In the previous week, Siga Technologies' average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
Siga Technologies	Neutral
Talphera	Neutral

Summary

Siga Technologies and Talphera tied by winning 7 of the 14 factors compared between the two stocks.

How does Talphera compare to Silverback Therapeutics?

Talphera (NASDAQ:TLPH) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Silverback Therapeutics' return on equity of -29.62% beat Talphera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-87.28%	-51.36%
Silverback Therapeutics	N/A	-29.62%	-28.20%

In the previous week, Talphera's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Talphera	Neutral
Silverback Therapeutics	Neutral

Talphera has higher revenue and earnings than Silverback Therapeutics. Talphera is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$1K	60,210.96	-$14.29M	-$0.27	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Talphera has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

37.7% of Talphera shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 3.5% of Talphera shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Talphera currently has a consensus target price of $3.00, suggesting a potential upside of 158.62%. Given Talphera's stronger consensus rating and higher probable upside, analysts clearly believe Talphera is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Talphera beats Silverback Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Talphera News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLPH vs. The Competition

Export

Metric	Talphera	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.73M	$12.48B	$7.26B	$13.14B
Dividend Yield	N/A	2.63%	2.57%	12.30%
P/E Ratio	-4.30	797.25	275.79	25.40
Price / Sales	60,210.96	950.97	695.58	114.44
Price / Cash	N/A	88.44	77.42	51.66
Price / Book	3.14	10.53	10.46	6.33
Net Income	-$14.29M	$2.82B	$3.49B	$358.33M
7 Day Performance	-6.45%	1.69%	0.59%	1.12%
1 Month Performance	-2.52%	0.83%	-2.01%	-2.67%
1 Year Performance	36.47%	3.90%	18.09%	6.01%

Talphera Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLPH Talphera	1.9503 of 5 stars	$1.16 -0.9%	$3.00 +158.6%	+24.3%	$60.73M	$1K	N/A	12
ZNTL Zentalis Pharmaceuticals	3.5193 of 5 stars	$3.13 -10.6%	$6.75 +115.7%	+108.7%	$250.85M	$67.43M	N/A	106	Analyst Forecast Gap Up
ACB Aurora Cannabis	1.0879 of 5 stars	$3.82 +0.3%	N/A	-25.3%	$247.05M	$247.82M	N/A	1,028	Analyst Downgrade
CRDL Cardiol Therapeutics	2.6638 of 5 stars	$1.85 -7.0%	$10.00 +440.5%	+68.9%	$231.19M	N/A	N/A	18	News Coverage
SIGA Siga Technologies	0.2908 of 5 stars	$2.98 -5.4%	N/A	-64.6%	$226.33M	$94.57M	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLPH) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Talphera (TLPH) Competitors

TLPH vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Talphera compare to Zentalis Pharmaceuticals?

Summary

How does Talphera compare to Aurora Cannabis?

Summary

How does Talphera compare to Cardiol Therapeutics?

Summary

How does Talphera compare to Siga Technologies?

Summary

How does Talphera compare to Silverback Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Talphera (TLPH) Competitors

TLPH vs. ZNTL, ACB, CRDL, SIGA, and SBTX

How does Talphera compare to Zentalis Pharmaceuticals?

Do analysts prefer TLPH or ZNTL?

Which has higher valuation and earnings, TLPH or ZNTL?

Which has more risk and volatility, TLPH or ZNTL?

Is TLPH or ZNTL more profitable?

Do insiders and institutionals hold more shares of TLPH or ZNTL?

Does the media refer more to TLPH or ZNTL?

Summary

How does Talphera compare to Aurora Cannabis?

Which has higher earnings and valuation, ACB or TLPH?

Is ACB or TLPH more profitable?

Do analysts rate ACB or TLPH?

Do institutionals and insiders believe in ACB or TLPH?

Does the media favor ACB or TLPH?

Which has more risk & volatility, ACB or TLPH?

Summary

How does Talphera compare to Cardiol Therapeutics?

Do insiders & institutionals believe in CRDL or TLPH?

Does the media favor CRDL or TLPH?

Which has preferable earnings and valuation, CRDL or TLPH?

Do analysts recommend CRDL or TLPH?

Which has more volatility & risk, CRDL or TLPH?

Is CRDL or TLPH more profitable?

Summary

How does Talphera compare to Siga Technologies?

Which has preferable earnings & valuation, SIGA or TLPH?

Do analysts rate SIGA or TLPH?

Do insiders and institutionals believe in SIGA or TLPH?

Is SIGA or TLPH more profitable?

Which has more volatility & risk, SIGA or TLPH?

Does the media favor SIGA or TLPH?

Summary

How does Talphera compare to Silverback Therapeutics?

Is TLPH or SBTX more profitable?

Does the media prefer TLPH or SBTX?

Which has stronger valuation and earnings, TLPH or SBTX?

Which has more risk & volatility, TLPH or SBTX?

Do insiders & institutionals hold more shares of TLPH or SBTX?

Do analysts prefer TLPH or SBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH vs. The Competition

Talphera Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools